U.S. market Closed. Opens in 2 days 3 hours 13 minutes

AVGR | Avinger, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.8500 - 1.9800
52 Week Range 1.5850 - 18.00
Beta N/A
Implied Volatility 240.37%
IV Rank 65.02%
Day's Volume 25,324
Average Volume 19,093
Shares Outstanding 1,586,430
Market Cap 3,109,403
Sector Healthcare
Industry Medical - Instruments & Supplies
IPO Date 2015-01-30
Valuation
Profitability
Growth
Health
P/E Ratio -0.13
Forward P/E Ratio N/A
EPS -15.10
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 68
Country USA
Website AVGR
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
*Chart delayed
Analyzing fundamentals for AVGR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see AVGR Fundamentals page.

Watching at AVGR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AVGR Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙